Markets
OSTX Watch
OS Therapiesorporated
$2.46
$0.08 3.64%
1 Min 5 Min 15 Min Hourly Daily
Assets Gross Profit Revenue Earnings
Chart Sentiment News Fundamentals About
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
32d agoSwungBullish
up 8.44% At 2.25, Now 2.44
I believe OS Therapies has solid momentum as we approach the important FDA meeting. With their recent developments and increased visibility, the stock... Read More
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
42d agoSwungBullish
up 28.3% At 1.59, Exited 2.04
I just see OSTX tightening its range, and if it breaks above $1.70 on volume, we could be looking at a move towards the $1.90–$2.00 level. The fundame... Read More
Exited 35d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
49d agoSwungBullish
up 4.58% At 1.53, Exited 1.6
I'm noticing a clear support around $1.45-$1.50 for OSTX, and with rising volume, it seems like momentum is building for a move back up. If it breaks ... Read More
Exited 42d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
53d agoSwungBullish
up 11.61% At 1.33, Exited 1.49
I just came across some exciting news about OS Therapies, including positive interim trial data for their lead candidate and a key FDA meeting request... Read More
Exited 46d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
86d agoInvestedBullish
up 48.72% At 1.64, Now 2.44
I've been keeping an eye on OS Therapies and with the positive Phase 2b trial results for OST-HER2 and their plans for commercial manufacturing, I bel... Read More
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
88d agoSwungBullish
up 5.84% At 1.54, Exited 1.63
I believe with OS Therapies gearing up for important clinical data expected in Q4 2024, and the confidence shown by the CEO in their innovative treatm... Read More
Exited 81d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
91d agoSwungBullish
down -3.01% At 1.66, Exited 1.61
I'm really excited about OS Therapies Inc. with their innovative treatment for osteosarcoma showing promise in trials. The recent $46 million funding ... Read More
Exited 84d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
106d agoInvestedBullish
up 29.73% At 1.88, Now 2.44
I'm really excited about OSTX after the recent patent news and the solid funding they've secured. With a clear path to FDA approval and a targeted mar... Read More
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
116d agoSwungBullish
up 15.54% At 1.93, Exited 2.23
I just see a lot of potential in OSTX after their recent strategic acquisition and ongoing clinical trials. With the upcoming request for Biologics Li... Read More
Exited 109d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
133d agoSwungBullish
down -36.99% At 2.92, Exited 1.84
I'm really bullish on OSTX given the positive trial results for OST-HER2. With no current FDA-approved treatments for a significant medical need, I se... Read More
Exited 126d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
136d agoSwungBullish
down -13.88% At 3.02, Exited 2.6
After the recent Phase 2b trial results showing significant improvements in cancer treatment, I believe OSTX is poised for a positive movement. The ma... Read More
Exited 129d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
147d agoSwungBullish
down -41.7% At 5.06, Exited 2.95
I'm feeling really bullish on OSTX right now, especially with the cup and handle pattern looking strong. The upcoming Phase 2b trial data could drive ... Read More
Exited 140d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
155d agoSwungBullish
up 19.35% At 4.29, Exited 5.12
I believe that OS Therapies is gearing up for a significant upward movement now that they've secured a partnership with B2i Digital. With upcoming Pha... Read More
Exited 148d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
158d agoSwungBullish
down -7.57% At 5.15, Exited 4.76
With the recent announcement of a securities purchase agreement that raises $6 million for OS Therapies, I'm optimistic about OSTX's potential for gro... Read More
Exited 151d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
164d agoSwungBullish
up 7.0% At 4.0, Exited 4.28
With OS Therapies showcasing impressive Phase II trial results and receiving FDA Fast Track designation, I see a strong opportunity here to capitalize... Read More
Exited 157d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
178d agoSwungBullish
up 63.6% At 2.5, Exited 4.09
I just watched OSTX bounce off the trendline support and I’m feeling bullish. If it breaks above $2.23, I expect it to push towards $2.50 and maybe ev... Read More
Exited 170d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
184d agoSwungBullish
up 82.59% At 2.01, Exited 3.67
I'm seeing potential in OS Therapies ($OSTX) due to their promising pipeline with OST-HER2 and the benefits that come with FDA orphan drug designation... Read More
Exited 177d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
191d agoSwungBullish
down -5.31% At 2.07, Exited 1.96
I just bought into OSTX because their innovative treatments for osteosarcoma and solid tumors look promising. With strong financial backing and a low ... Read More
Exited 184d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
234d agoSwungBullish
down -0.33% At 3.01, Exited 3.0
I'm seeing a potential bullish recovery for OSTX after its recent clinical trial completion, and the after-hours pop suggests there might be positive ... Read More
Exited 227d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
235d agoInvestedBullish
up 64.89% At 2.82, Exited 4.65
I'm really bullish on OS Therapies (OSTX) with their focus on tackling osteosarcoma and strong clinical momentum. The ADC market is booming, and OSTX ... Read More
Exited 144d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
242d agoSwungBullish
down -4.14% At 3.14, Exited 3.01
I see OSTX forming a bullish cup and handle pattern, and after a recent 20% increase, consolidation seems likely before a breakout. With positive news... Read More
Exited 235d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
269d agoSwungBullish
down -14.84% At 4.14, Exited 3.53
I'm excited about $OSTX as it's just 11% away from its all-time high of $4.60. If it breaks through that level, I believe we could see a strong uptren... Read More
Exited 262d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
276d agoInvestedBullish
down -55.53% At 3.98, Exited 1.77
I believe OS Therapies is on the verge of a significant breakthrough with their OST-HER2 treatment, especially with the upcoming topline data expected... Read More
Exited 199d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
280d agoDaytradedBullish
up 5.08% At 3.94, Exited 4.14
OS Therapies ($OSTX) gained serious attention and saw a 5% jump in after-hours trading on Thursday after getting recognition from major investor commu... Read More
Exited 277d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
294d agoInvestedBullish
down -32.31% At 3.25, Exited 2.2
Given OSTX's proactive advancements in their Phase 2b clinical trials and the significant revenue potential from out-licensing deals, I believe the st... Read More
Exited 203d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought OSTX Shares
295d agoInvestedBullish
down -20.25% At 3.16, Exited 2.52
With recent media exposure and strong potential in developing innovative cancer treatments, I believe OSTX is positioned for significant growth. Their... Read More
Exited 205d ago
0 0
Sign in or create an account Get notifications, save trades, and more
google logo Continue with Google Continue with Email
By continuing, you agree to our Terms and Privacy Policy.